|

Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Istituto Clinico Humanitas1

Indications

  • Relapsed or Refractory Lymphoma1
  • B-Cell Lymphoma Treatment1
  • High-grade B-cell Lymphoma (HGBCL)1
  • Diffuse Large B-Cell Lymphoma1
  • Cancer1

Other1 trial

Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.